HCPLive

Tovinontrine Reduces NT-proBNP in HFrEF, May Have Greater Benefit at Smaller Doses

Oct 12, 2026 · 0:06:36

Listen to Episode

✨ AI Summary

Tovinontrine reduced NT-proBNP in HFrEF patients in Cycle-1-REF trial.
Potential for greater benefit at smaller doses noted.
James Udelson, MD, presented findings at HFSA 2026.

Guests on This Episode

JM

James Udelson, MD

2 podcast appearances

More from HCPLive

Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites

Oct 12, 2026 · 0:03:18

Targeting Senescent Cells in Actinic Keratosis With RLS-1496

Oct 12, 2026 · 0:04:25

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Oct 12, 2026 · 0:03:33

Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF

Oct 12, 2026 · 0:06:00

View all episodes →